Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter,Open-label,Single Arm,Multiple-dose Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

NCT07266090 is registered in ClinicalTrials.gov with Viatris Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07266090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07266090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter,Open-label,Single Arm,Multiple-dose Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
Lead sponsor
Viatris Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 14, 2026
Completion date
October 8, 2027
Enrollment
15 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sle - systemic lupus erythematosus